Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of TSN222 in Subjects With Advanced Solid Tumors or Lymphoma

NCT05842785 is registered in ClinicalTrials.gov with Tyligand Bioscience (Shanghai) Limited as lead sponsor.

NCT NCT05842785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05842785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of TSN222 in Subjects With Advanced Solid Tumors or Lymphoma
Lead sponsor
Tyligand Bioscience (Shanghai) Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 26, 2023
Completion date
June 1, 2026
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

has a pathologically documented unresectable locally advanced or metastatic solid tumor or lymphoma